Qureight Jun 17 2025 Qureight, a deep-learning analytics company accelerating drug development through AI-powered data curation, today announced that its digitally-twinned synthetic control arm has been used in a breakthrough clinical trial application in place of a human placebo group, marking a world-first in lung disease research. The study, presented at the American Thoracic Society, demonstrates significant clinical efficacy for Avalyn's inhaled pirfenidone (AP01), a promising treatment